Alzheimer’s disease (AD) is a devastating neurodegenerative disease with no cure currently available. A pathological hallmark of AD is accumulation and deposition of amyloid-β protein (Aβ), a ∼4 kDa peptide generated through serial cleavage of the amyloid-β protein precursor (AβPP) by β- and γ-secretases. Curcumin is a natural compound primarily found in the widely used culinary spice, turmeric, which displays therapeutic potential for AD. Recently, we reported the development of curcumin analogs and identified a lead compound, curcumin-like compound-R17 (CLC-R17), that significantly attenuates Aβ deposition in an AD transgenic mouse model. Here, we elucidated the mechanisms of this analog on Aβ levels and AβPP processing using cell models of AD. Using biochemical methods and our recently developed nanoplasmonic fiber tip probe technology, we showed that the lead compound potently lowers Aβ levels in conditioned media and reduces oligomeric amyloid levels in the cells. Furthermore, like curcumin, the lead compound attenuates the maturation of AβPP in the secretory pathway. Interestingly, it upregulated α-secretase processing of AβPP and inhibited β-secretase processing of AβPP by decreasing BACE1 protein levels. Collectively, our data reveal mechanisms of a promising curcumin analog in reducing Aβ levels, which strongly support its development as a potential therapeutic for AD.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
2.
BertramL, TanziRE (2008) Thirty years of Alzheimer’s disease genetics: The implications of systematic meta-analyses. Nat Rev Neurosci9, 768–778.
3.
GandyS (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest115, 1121–1129.
4.
ChoiSH, KimYH, HebischM, SliwinskiC, LeeS, D’AvanzoC, ChenH, HooliB, AsselinC, MuffatJ, KleeJB, ZhangC, WaingerBJ, PeitzM, KovacsDM, WoolfCJ, WagnerSL, TanziRE, KimDY (2014) A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature515, 274–278.
5.
NilssonP, SekiguchiM, AkagiT, IzumiS, KomoriT, HuiK, SorgjerdK, TanakaM, SaitoT, IwataN, SaidoTC (2015) Autophagy-related protein 7 deficiency in amyloid beta (Abeta) precursor protein transgenic mice decreases Abeta in the multivesicular bodies and induces Abeta accumulation in the Golgi. Am J Pathol185, 305–313.
6.
SannerudR, EsselensC, EjsmontP, MatteraR, RochinL, TharkeshwarAK, De BaetsG, De WeverV, HabetsR, BaertV, VermeireW, MichielsC, GrootAJ, WoutersR, DillenK, VintsK, BaatsenP, MunckS, DeruaR, WaelkensE, BasiGS, MerckenM, VooijsM, BollenM, SchymkowitzJ, RousseauF, BonifacinoJS, Van NielG, De StrooperB, AnnaertW (2016) Restricted location of PSEN2/gamma-secretase determines substrate specificity and generates an intracellular Abeta pool. Cell166, 193–208.
7.
WalshDM, TsengBP, RydelRE, PodlisnyMB, SelkoeDJ (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry39, 10831–10839.
8.
MasliahE, SiskA, MalloryM, MuckeL, SchenkD, GamesD (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer’s disease. J Neurosci16, 5795–5811.
TurnerRS, SuzukiN, ChyungAS, YounkinSG, LeeVM (1996) Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem271, 8966–8970.
11.
SkovronskyDM, DomsRW, LeeVM (1998) Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol141, 1031–1039.
12.
LeeEB, SkovronskyDM, AbtahianF, DomsRW, LeeVM (2003) Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J Biol Chem278, 4458–4466.
13.
TakedaK, ArakiW, TabiraT (2004) Enhanced generation of intracellular Abeta42 amyloid peptide by mutation of presenilins PS1 and PS2. Eur J Neurosci19, 258–264.
14.
GourasGK, TampelliniD, TakahashiRH, Capetillo-ZarateE (2010) Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol119, 523–541.
15.
GourasGK, TsaiJ, NaslundJ, VincentB, EdgarM, CheclerF, GreenfieldJP, HaroutunianV, BuxbaumJD, XuH, GreengardP, RelkinNR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol156, 15–20.
16.
OakleyH, ColeSL, LoganS, MausE, ShaoP, CraftJ, Guillozet-BongaartsA, OhnoM, DisterhoftJ, Van EldikL, BerryR, VassarR (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci26, 10129–10140.
BilousovaT, MillerCA, PoonWW, VintersHV, CorradaM, KawasC, HaydenEY, TeplowDB, GlabeC, AlbayR3rd, ColeGM, TengE, GylysKH (2016) Synaptic amyloid-beta oligomers precede p-Tau and differentiate high pathology control cases. Am J Pathol186, 185–198.
19.
PensalfiniA, AlbayR3rd, RasoolS, WuJW, HatamiA, AraiH, MargolL, MiltonS, PoonWW, CorradaMM, KawasCH, GlabeCG (2014) Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol Dis71, 53–61.
20.
LimGP, ChuT, YangF, BeechW, FrautschySA, ColeGM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci21, 8370–8377.
21.
YangF, LimGP, BegumAN, UbedaOJ, SimmonsMR, AmbegaokarSS, ChenPP, KayedR, GlabeCG, FrautschySA, ColeGM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem280, 5892–5901.
22.
WangYJ, ThomasP, ZhongJH, BiFF, KosarajuS, PollardA, FenechM, ZhouXF (2009) Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer’s disease mouse. Neurotox Res15, 3–14.
23.
Garcia-AllozaM, BorrelliLA, RozkalneA, HymanBT, BacskaiBJ (2007) Curcumin labels amyloid pathology in vivo disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem102, 1095–1104.
24.
SmallGW, SiddarthP, LiZ, MillerKJ, ErcoliL, EmersonND, MartinezJ, WongKP, LiuJ, MerrillDA, ChenST, HenningSM, SatyamurthyN, HuangSC, HeberD, BarrioJR (2018) Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry26, 266–277.
25.
CalabreseV, ScapagniniG, ColombritaC, RavagnaA, PennisiG, Giuffrida StellaAM, GalliF, ButterfieldDA (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: A nutritional approach. Amino Acids25, 437–444.
KelloffGJ, BooneCW, CrowellJA, NayfieldSG, HawkET, SteeleVE, LubetRA, SigmanCC (1997) Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res396, 159–183.
28.
ZhangC, BrowneA, ChildD, TanziRE (2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem285, 28472–28480.
29.
HongW, LiangF, SchaakD, LoncarM, QuanQ (2014) Nanoscale label-free bioprobes to detect intracellular proteins in single living cells. Sci Rep4, 6179.
30.
LiangF, WanY, SchaakD, WardJ, ShenX, TanziRE, ZhangC, QuanQ (2017) Nanoplasmonic fiber tip probe detects significant reduction of intracellular Alzheimer’s disease-related oligomers by curcumin. Sci Rep7, 5722.
31.
RavindranathV, ChandrasekharaN (1980) Absorption and tissue distribution of curcumin in rats. Toxicology16, 259–265.
32.
ZhangX, TianY, ZhangC, TianX, RossAW, MoirRD, SunH, TanziRE, MooreA, RanC (2015) Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. Proc Natl Acad Sci U S A112, 9734–9739.
33.
WangH, SangN, ZhangC, RaghupathiR, TanziRE, SaundersA (2015) Cathepsin L mediates the degradation of novel APP C-terminal fragments. Biochemistry54, 2806–2816.
LiangF, ZhangY, HongW, DongY, XieZ, QuanQ (2016) Direct tracking of amyloid and tu dynamics in neuroblastoma cells using nanoplasmonic fiber tip probes. Nano Lett16, 3989–3994.
ZhangC, BrowneA, ChildD, DivitoJR, StevensonJA, TanziRE (2010) Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein. J Biol Chem285, 8515–8526.
38.
WardJ, WangH, SaundersAJ, TanziRE, ZhangC (2017) Mechanisms that synergistically regulate eta-secretase processing of APP and Aeta-alpha protein levels: Relevance to pathogenesis and treatment of Alzheimer’s disease. Discov Med23, 121–128.
39.
KounnasMZ, DanksAM, ChengS, TyreeC, AckermanE, ZhangX, AhnK, NguyenP, ComerD, MaoL, YuC, PleynetD, DigregorioPJ, VelicelebiG, StaudermanKA, ComerWT, MobleyWC, LiYM, SisodiaSS, TanziRE, WagnerSL (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. Neuron67, 769–780.
40.
ZhangC, GriciucA, HudryE, WanY, QuintiL, WardJ, ForteAM, ShenX, RanC, ElmalehDR, TanziRE (2018) Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid beta-protein by promoting microglial phagocytosis. Sci Rep8, 1144.
41.
ZhangC, BrowneA, KimDY, TanziRE (2010) Familial Alzheimer’s disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage. Curr Alzheimer Res7, 21–26.
42.
ZhangC, BrowneA, DivitoJR, StevensonJA, RomanoD, DongY, XieZ, TanziRE (2010) Amyloid-beta production via cleavage of amyloid-beta protein precursor is modulated by cell density. J Alzheimers Dis22, 683–984.
43.
LiuH, LiZ, QiuD, GuQ, LeiQ, MaoL (2010) The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett485, 83–88.
ZhuY, BuS (2017) Curcumin induces autophagy, apoptosis, and cell cycle arrest in human pancreatic cancer cells. Evid Based Complement Alternat Med2017, 5787218.
47.
YangDS, StavridesP, MohanPS, KaushikS, KumarA, OhnoM, SchmidtSD, WessonD, BandyopadhyayU, JiangY, PawlikM, PeterhoffCM, YangAJ, WilsonDA, St George-HyslopP, WestawayD, MathewsPM, LevyE, CuervoAM, NixonRA (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits. Brain134, 258–277.
48.
GandyS, ZhangYW, IkinA, SchmidtSD, LevyE, SheffieldR, NixonRA, LiaoFF, MathewsPM, XuH, EhrlichME (2007) Alzheimer’s presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. J Neurochem102, 619–626.
49.
XiaW, ZhangJ, KholodenkoD, CitronM, PodlisnyMB, TeplowDB, HaassC, SeubertP, KooEH, SelkoeDJ (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem272, 7977–7982.
50.
HaassC, LemereCA, CapellA, CitronM, SeubertP, SchenkD, LannfeltL, SelkoeDJ (1995) The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat Med1, 1291–1296.
51.
YoshidaH, OkumuraN, NishimuraY, KitagishiY, MatsudaS (2011) Turmeric and curcumin suppress presenilin 1 protein expression in Jurkat cells. Exp Ther Med2, 629–632.
52.
XiongZ, HongmeiZ, LuS, YuL (2011) Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer’s disease. Pharmacol Rep63, 1101–1108.
53.
LiuL, DingL, RovereM, WolfeMS, SelkoeDJ (2019) A cellular complex of BACE1 and gamma-secretase sequentially generates Abeta from its full-length precursor. J Cell Biol218, 644–663.
54.
LapchakPA, SchubertDR, MaherPA (2011) Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem116, 122–131.
55.
MaherP, AkaishiT, SchubertD, AbeK (2010) A pyrazole derivative of curcumin enhances memory. Neurobiol Aging31, 706–709.
56.
ChirutaC, ZhaoY, TangF, WangT, SchubertD (2013) Metabolism of a potent neuroprotective hydrazide. Bioorg Med Chem21, 2733–2741.
57.
PriorM, DarguschR, EhrenJL, ChirutaC, SchubertD (2013) The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther5, 25.
58.
HongHS, RanaS, BarriganL, ShiA, ZhangY, ZhouF, JinLW, HuaDH (2009) Inhibition of Alzheimer’s amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem108, 1097–1108.
59.
MaQL, ZuoX, YangF, UbedaO, GantD, AlaverdyanM, TengE, HuS, ChenPP, MaitiP, TeterB, ColeGM, FrautschySA (2013) Curcumin suppresses soluble tau oligomers and corrects molecular chaperone, synaptic and behavioral deficits in aged human tau transgenic mice. J Biol Chem288, 4056–4065.
60.
KelloffGJ, BooneCW, CrowellJA, SteeleVE, LubetRA, DoodyLA, MaloneWF, HawkET, SigmanCC (1996) New agents for cancer chemoprevention. J Cell Biochem Suppl26, 1–28.
61.
YangYS, SuYF, YangHW, LeeYH, ChouJI, UengKC (2014) Lipid-lowering effects of curcumin in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Phytother Res28, 1770–1777.
62.
ChengAL, HsuCH, LinJK, HsuMM, HoYF, ShenTS, KoJY, LinJT, LinBR, Ming-ShiangW, YuHS, JeeSH, ChenGS, ChenTM, ChenCA, LaiMK, PuYS, PanMH, WangYJ, TsaiCC, HsiehCY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res21, 2895–2900.
63.
ZhangC (2017) Developing effective therapeutics for Alzheimer’s disease – emerging mechanisms and actions in translational medicine. Discov Med23, 105–111.
64.
PerryD, SperlingR, KatzR, BerryD, DiltsD, HannaD, SallowayS, TrojanowskiJQ, BountraC, KramsM, LuthmanJ, PotkinS, GribkoffV, TempleR, WangY, CarrilloMC, StephensonD, SnyderH, LiuE, WareT, McKewJ, FieldsFO, BainLJ, BensC (2015) Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Rev Neurother15, 327–333.
